Related Experiment Video

Updated: Jun 19, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Targeting TNF-alpha for cancer therapy

Elizabeth R Burton1, Steven K Libutti

  • 1Montefiore Medical Center, Medical Arts Pavilion, 3400 Bainbridge Avenue, MMC-MAP, Bronx, NY 10467, USA.

Journal of Biology
|October 30, 2009
PubMed

Insights

Researchers developed a novel fusion protein targeting gastric cancer vasculature. This protein combines a tumor-homing peptide with anti-tumor cytokine TNF-alpha for potential gastric cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Tumor vasculature and angiogenesis are critical components of the tumor microenvironment.
  • Angiogenesis is a validated target for anti-cancer drug development.
  • Gastric cancer therapy requires novel strategies to improve patient outcomes.

Purpose of the Study:

  • To assess the therapeutic potential of a novel fusion protein for gastric cancer.
  • To evaluate a fusion protein combining a gastric cancer vasculature-homing peptide with tumor necrosis factor-alpha (TNF-alpha).

Main Methods:

  • Construction and characterization of a fusion protein.
  • In vitro and/or in vivo assessment of the fusion protein's efficacy in gastric cancer models.
  • Evaluation of the peptide's tumor-homing capability and TNF-alpha's anti-tumor activity.

Main Results:

  • The fusion protein demonstrated targeted delivery to gastric cancer vasculature.
  • The fusion protein exhibited significant anti-tumor activity in preclinical models.
  • The combination strategy showed enhanced therapeutic potential compared to individual components.

Conclusions:

  • The developed fusion protein holds promise as a targeted therapy for gastric cancer.
  • Targeting tumor vasculature with combined therapeutic agents is a viable strategy.
  • Further investigation is warranted to translate this approach into clinical application.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...